The general population in China may start getting access to locally manufactured Covid-19 vaccines from November or December, according to a top scientist from the Chinese Centre for Disease Control and Prevention (CDC).
During a programme telecast by state broadcaster CCTV this week, Wu Guizhen, the CDC's chief biosafety expert said that preparations are underway for some vaccines to go into mass production.
The top scientists also talked about the smooth progress of several vaccine candidates that are in clinical trials, the South China Morning Post reported on Tuesday (15 August).
"I joined the experimental group and had a coronavirus shot in April," Wu said in the programme.
"I've felt quite good in the past few months, nothing abnormal. The process of inoculation did not cause any localised pain."
At least five vaccine candidates developed by China have reached the crucial phase-3 stage, while Russia last month approved a Covid-19 vaccine before the completion of Phase-3 trials.
Wu said that she was hopeful about the efficacy and safety of the vaccine candidates developed by China.
"We expect them to remain effective for one to three years a (but) the results will need to be observed for a longer time," she said.
China's military received approval for using a Covid-19 vaccine jointly developed by its research unit and CanSino Biologics Inc. in June itself.
The approval for the Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) was granted by the Health Bureau of the Logistics Support Department of China's Central Military Commission on June 25, for one year.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.